Novel kinase targets as emerging therapies for multiple myeloma

At the Myeloma 2015 meeting, Dr Sergio Giralt (Memorial Sloan-Kettering Cancer Center, New York, NY) chairs a discussion with Prof Faith Davies (The University of Arkansas for Medical Sciences (UAMS), Little Rock, AR) and Prof Shaji Kumar (Mayo Clinic, Rochester, MN) on their studies of novel kinase inhibitors in clinical development for the treatment of multiple myeloma. They focus on inhibitors of mitogen-activated protein kinase kinase (MEK) and Provirus Integration site for Moloney leukemia (PIM) kinases.

Share this video  
11th April 2015